Literature DB >> 12381502

Open-label olanzapine in obsessive-compulsive disorder refractory to antidepressant treatment.

M A Crocq1, Ph Leclercq, M S Guillon, P E Bailey.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381502     DOI: 10.1016/s0924-9338(02)00673-9

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


× No keyword cloud information.
  6 in total

1.  Clinical treatment of obsessive compulsive disorder.

Authors:  Christopher Pittenger; Ben Kelmendi; Michael Bloch; John H Krystal; Vladimir Coric
Journal:  Psychiatry (Edgmont)       Date:  2005-11

Review 2.  Childhood anxiety disorders and developmental issues in anxiety.

Authors:  Paul Arnold; S Preeya Banerjee; Rashmi Bhandari; Elisa Lorch; Jennifer Ivey; Michelle Rose; David R Rosenberg
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

Review 3.  Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; John H Krystal; Vladimir Coric
Journal:  NeuroRx       Date:  2006-01

4.  Obsessive-compulsive spectrum disorders.

Authors:  Andrea Allen; Audrey King; Eric Hollander
Journal:  Dialogues Clin Neurosci       Date:  2003-09       Impact factor: 5.986

5.  Quetiapine augmentation of SRIs in treatment refractory obsessive-compulsive disorder: a double-blind, randomised, placebo-controlled study [ISRCTN83050762].

Authors:  Paul D Carey; Bavanisha Vythilingum; Soraya Seedat; Jacqueline E Muller; Michael van Ameringen; Dan J Stein
Journal:  BMC Psychiatry       Date:  2005-01-24       Impact factor: 3.630

Review 6.  Critical Review of the Use of Second-Generation Antipsychotics in Obsessive-Compulsive and Related Disorders.

Authors:  Dongmi Kim; Nicole L Ryba; Julie Kalabalik; Ligia Westrich
Journal:  Drugs R D       Date:  2018-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.